Vertex Pharmaceuticals SVP Unloads $180,342 in Stock (VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX) SVP Paul M. Silva sold 2,027 shares of the stock in a transaction that occurred on Thursday, July 31st. The shares were sold at an average price of $88.97, for a total value of $180,342.19. Following the completion of the transaction, the senior vice president now directly owns 17,000 shares in the company, valued at approximately $1,512,490. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 1.55% on Friday, hitting $87.53. 2,479,442 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a 1-year low of $58.06 and a 1-year high of $99.74. The stock’s 50-day moving average is $89.28 and its 200-day moving average is $77.98. The company’s market cap is $20.773 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings data on Tuesday, July 29th. The company reported ($0.61) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.71) by $0.10. The company had revenue of $138.42 million for the quarter, compared to the consensus estimate of $131.85 million. During the same quarter last year, the company posted ($0.03) earnings per share. Vertex Pharmaceuticals’s revenue was down 55.5% compared to the same quarter last year. Analysts expect that Vertex Pharmaceuticals will post $-2.85 EPS for the current fiscal year.
A number of analysts have recently weighed in on VRTX shares. Analysts at Zacks reiterated a “neutral” rating on shares of Vertex Pharmaceuticals in a research note on Thursday. They now have a $97.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 9th. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Vertex Pharmaceuticals has a consensus rating of “Hold” and an average target price of $102.82.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.